Welcome to LookChem.com Sign In|Join Free
  • or
3-[2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-6-(1H-indazol-5-ylamino)pyrimidin-4-yl]phenol is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

701243-16-5

Post Buying Request

701243-16-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

701243-16-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 701243-16-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,0,1,2,4 and 3 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 701243-16:
(8*7)+(7*0)+(6*1)+(5*2)+(4*4)+(3*3)+(2*1)+(1*6)=105
105 % 10 = 5
So 701243-16-5 is a valid CAS Registry Number.

701243-16-5Downstream Products

701243-16-5Relevant academic research and scientific papers

Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors

Pecchi, Sabina,Renhowe, Paul A.,Taylor, Clarke,Kaufman, Susan,Merritt, Hanne,Wiesmann, Marion,Shoemaker, Kevin R.,Knapp, Mark S.,Ornelas, Elizabeth,Hendrickson, Thomas F.,Fantl, Wendy,Voliva, Charles F.

supporting information; scheme or table, p. 6895 - 6898 (2011/02/26)

PI3 Kinases are a family of lipid kinases mediating numerous cell processes such as proliferation, migration, and differentiation. The PI3 kinase pathway is often de-regulated in cancer through PI3Kα overexpression, gene amplification, mutations, and PTEN

2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER

-

Page 62; 70, (2008/06/13)

Compounds having formula I are provided where the variables have the values described herein. (I). Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and combinations with other agents. A method of treating a patient comprises administering a pharmaceutical formulation according to the invention to a patient in need thereof.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 701243-16-5